These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23462180)

  • 21. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients.
    Neumann A; Polis M; Rozenberg L; Jackson J; Reitano K; McLaughlin M; Koratich C; Dewar R; Masur H; Haagmans B; Kottilil S
    AIDS; 2007 Sep; 21(14):1855-65. PubMed ID: 17721093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiviral potency analysis and functional comparison of consensus interferon, interferon-alpha2a and pegylated interferon-alpha2b against hepatitis C virus infection.
    Erickson AK; Seiwert S; Gale M
    Antivir Ther; 2008; 13(7):851-62. PubMed ID: 19043919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IFN-stimulated gene expression is a useful potential molecular marker of response to antiviral treatment with Peg-IFNα 2b and ribavirin in patients with hepatitis C virus genotype 1.
    Sixtos-Alonso MS; Sánchez-Muñoz F; Sánchez-Ávila JF; Martínez RA; Domínguez López A; Vargas Vorácková F; Uribe M
    Arch Med Res; 2011 Jan; 42(1):28-33. PubMed ID: 21376259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitory effect of a triterpenoid compound, with or without alpha interferon, on hepatitis C virus infection.
    Watanabe T; Sakamoto N; Nakagawa M; Kakinuma S; Itsui Y; Nishimura-Sakurai Y; Ueyama M; Funaoka Y; Kitazume A; Nitta S; Kiyohashi K; Murakawa M; Azuma S; Tsuchiya K; Oooka S; Watanabe M
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2537-45. PubMed ID: 21444704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C virus replication in mouse cells is restricted by IFN-dependent and -independent mechanisms.
    Nandakumar R; Finsterbusch K; Lipps C; Neumann B; Grashoff M; Nair S; Hochnadel I; Lienenklaus S; Wappler I; Steinmann E; Hauser H; Pietschmann T; Kröger A
    Gastroenterology; 2013 Dec; 145(6):1414-23.e1. PubMed ID: 23973921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8.
    Tokumoto Y; Hiasa Y; Uesugi K; Watanabe T; Mashiba T; Abe M; Kumagi T; Ikeda Y; Matsuura B; Onji M
    J Infect Dis; 2012 Apr; 205(7):1121-30. PubMed ID: 22357660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication.
    Metz P; Dazert E; Ruggieri A; Mazur J; Kaderali L; Kaul A; Zeuge U; Windisch MP; Trippler M; Lohmann V; Binder M; Frese M; Bartenschlager R
    Hepatology; 2012 Dec; 56(6):2082-93. PubMed ID: 22711689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics.
    Marcello T; Grakoui A; Barba-Spaeth G; Machlin ES; Kotenko SV; MacDonald MR; Rice CM
    Gastroenterology; 2006 Dec; 131(6):1887-98. PubMed ID: 17087946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Caffeic acid inhibits HCV replication via induction of IFNα antiviral response through p62-mediated Keap1/Nrf2 signaling pathway.
    Shen J; Wang G; Zuo J
    Antiviral Res; 2018 Jun; 154():166-173. PubMed ID: 29656059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatic IFN-Induced Protein with Tetratricopeptide Repeats Regulation of HCV Infection.
    Ishida Y; Kakuni M; Bang BR; Sugahara G; Lau DT; Tateno-Mukaidani C; Li M; Gale M; Saito T
    J Interferon Cytokine Res; 2019 Mar; 39(3):133-146. PubMed ID: 30844328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiviral action of interferon-alpha against hepatitis C virus replicon and its modulation by interferon-gamma and interleukin-8.
    Jia Y; Wei L; Jiang D; Wang J; Cong X; Fei R
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1278-85. PubMed ID: 17565587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel alpha interferon (IFN-alpha) variant with improved inhibitory activity against hepatitis C virus genotype 1 replication compared to IFN-alpha2b therapy in a subgenomic replicon system.
    Escuret V; Martin A; Durantel D; Parent R; Hantz O; Trépo C; Menguy T; Bottius E; Dardy J; Maral J; Escary JL; Zoulim F
    Antimicrob Agents Chemother; 2006 Dec; 50(12):3984-91. PubMed ID: 17030563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selection of genetic variants of the 5' noncoding region of hepatitis C virus occurs only in patients responding to interferon alpha therapy.
    Lu M; Wiese M; Roggendorf M
    J Med Virol; 1999 Oct; 59(2):146-53. PubMed ID: 10459148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Control of temporal activation of hepatitis C virus-induced interferon response by domain 2 of nonstructural protein 5A.
    Hiet MS; Bauhofer O; Zayas M; Roth H; Tanaka Y; Schirmacher P; Willemsen J; Grünvogel O; Bender S; Binder M; Lohmann V; Lotteau V; Ruggieri A; Bartenschlager R
    J Hepatol; 2015 Oct; 63(4):829-37. PubMed ID: 25908268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo.
    Abe H; Imamura M; Hiraga N; Tsuge M; Mitsui F; Kawaoka T; Takahashi S; Ochi H; Maekawa T; Hayes CN; Tateno C; Yoshizato K; Murakami S; Yamashita N; Matsuhira T; Asai K; Chayama K
    J Hepatol; 2011 Jul; 55(1):11-8. PubMed ID: 21145867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis C virus non-structural 5A abrogates signal transducer and activator of transcription-1 nuclear translocation induced by IFN-alpha through dephosphorylation.
    Gong GZ; Cao J; Jiang YF; Zhou Y; Liu B
    World J Gastroenterol; 2007 Aug; 13(30):4080-4. PubMed ID: 17696225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ribavirin enhances the action of interferon-α against hepatitis C virus by promoting the p53 activity through the ERK1/2 pathway.
    Liu WL; Yang HC; Su WC; Wang CC; Chen HL; Wang HY; Huang WH; Chen DS; Lai MY
    PLoS One; 2012; 7(9):e43824. PubMed ID: 22962590
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon alpha (IFNα)-induced TRIM22 interrupts HCV replication by ubiquitinating NS5A.
    Yang C; Zhao X; Sun D; Yang L; Chong C; Pan Y; Chi X; Gao Y; Wang M; Shi X; Sun H; Lv J; Gao Y; Zhong J; Niu J; Sun B
    Cell Mol Immunol; 2016 Jan; 13(1):94-102. PubMed ID: 25683609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peroxisome proliferator-activated receptor delta antagonists inhibit hepatitis C virus RNA replication.
    Ban S; Ueda Y; Ohashi M; Matsuno K; Ikeda M; Kato N; Miyachi H
    Bioorg Med Chem Lett; 2013 Sep; 23(17):4774-8. PubMed ID: 23891183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New drugs for hepatitis C virus (HCV).
    Clarke BE
    Baillieres Best Pract Res Clin Gastroenterol; 2000 Apr; 14(2):293-305. PubMed ID: 10890323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.